Cargando…
Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis
IMPORTANCE: Ospemifene is a novel selective estrogen receptor modulator developed for the treatment of moderate to severe postmenopausal vulvovaginal atrophy (VVA). OBJECTIVE: The aim of the study is to perform a systematic literature review (SLR) and network meta-analysis (NMA) to assess the effica...
Autores principales: | Simon, James A., Ferenczy, Alex, Black, Denise, Castonguay, Alex, Royer, Catherine, Marouf, Rafik, Beauchemin, Catherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389189/ https://www.ncbi.nlm.nih.gov/pubmed/37369079 http://dx.doi.org/10.1097/GME.0000000000002211 |
Ejemplares similares
-
Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy
por: Shin, Jae Jun, et al.
Publicado: (2017) -
Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies
por: Salcedo, Félix Lugo, et al.
Publicado: (2020) -
Experience with ospemifene in a patient with vulvovaginal atrophy and dyslipidemia: a case study
por: Rodríguez, Silvia Pilar González
Publicado: (2020) -
Ospemifene for vulvar and vaginal atrophy: an overview
por: Palacios, Santiago
Publicado: (2020) -
Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy
por: Goldstein, S. R., et al.
Publicado: (2014)